Scarica l'app Stockscreener
7.555
3.20%
-0.25
Dopo l'orario di chiusura:
7.55
-0.005
-0.07%
Precedente Chiudi:
$7.805
Aprire:
$7.98
Volume 24 ore:
138.33K
Relative Volume:
1.47
Capitalizzazione di mercato:
$727.80M
Reddito:
$116.59M
Utile/perdita netta:
$9.88M
Rapporto P/E:
353.04
EPS:
0.0214
Flusso di cassa netto:
$-505.00K
1 W Prestazione:
-2.01%
1M Prestazione:
-5.80%
6M Prestazione:
-3.51%
1 anno Prestazione:
-36.83%
Intervallo 1D:
$7.55
$8.01
Intervallo di 1 settimana:
$7.475
$8.51
Portata 52W:
$6.11
$12.62
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Nome
Gyre Therapeutics Inc
Settore
Industria
Telefono
(858) 567-7770
Indirizzo
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.555 | 727.80M | 116.59M | 9.88M | -505.00K | 0.0214 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | Jefferies | Buy |
| 2025-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-11 | Iniziato | Noble Capital Markets | Outperform |
| 2021-04-29 | Ripresa | Stephens | Overweight |
| 2021-02-10 | Iniziato | Piper Sandler | Overweight |
| 2020-05-21 | Iniziato | Raymond James | Outperform |
| 2019-01-04 | Iniziato | Oppenheimer | Outperform |
| 2018-02-12 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Reiterato | Chardan Capital Markets | Buy |
| 2017-12-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Iniziato | Chardan Capital Markets | Buy |
| 2017-06-06 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-06-30 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Gyre Therapeutics Inc Borsa (GYRE) Ultime notizie
Gyre Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Gyre Therapeutics Stock (ISIN: KYG4200L1031) Faces Pressure After Q4 Earnings Miss Amid Pipeline Mom - AD HOC NEWS
Gyre Therapeutics Sees Stable $100 Million Lung Fibrosis Drug Revenue - marketscreener.com
Volatility Watch: Whats Gyre Therapeutics Incs historical returnTrade Performance Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen - TipRanks
Gyre Therapeutics (GYRE) Q4 Loss Challenges Bullish Margin Durability Narratives - simplywall.st
Gyre Therapeutics, Inc. (GYRE) Q4 earnings miss estimates - MSN
Gyre Therapeutics (GYRE) Posts Q4 FY25 Loss of $0.02; misses estimates - AlphaStreet
Gyre Therapeutics, Inc. (GYRE) Q4 Results Fall Short of Expectations - Bitget
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs - TipRanks
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates - Yahoo Finance
Gyre Therapeutics, Inc. Provides Revenues Outlook for 2026 - marketscreener.com
GYRE | Gyre Therapeutics, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Gyre Therapeutics Q4 revenue beats estimates on new product launch - TradingView
Gyre Therapeutics Swings to Net Loss in Q4, Revenue Increases - marketscreener.com
Gyre Therapeutics (NASDAQ: GYRE) details F351, ETUARY and CG001419 outlook at investor conference - Stock Titan
Gyre Therapeutics reports fourth quarter and full year 2025 financial results - marketscreener.com
(GYRE) Gyre Therapeutics Expects 2026 Revenue Range $100.5M to $111.0M, vs. FactSet Est of $148.0M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Revenue $37.2M, vs. FactSet Est of $35.4M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Loss $0.02 a Share, vs. FactSet Est of $0.06 EPS - marketscreener.com
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports 10% Revenue Growth in Full-Year 2025 and Announces Acquisition of Cullgen - Quiver Quantitative
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Earnings Update: Can Gyre Therapeutics Inc maintain its current growth rateJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpTime to Buy? - MarketBeat
GYRE Technical Analysis & Stock Price Forecast - Intellectia AI
GYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - Quantisnow
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction - Yahoo Finance
GNI Group’s Gyre Therapeutics to acquire Cullgen in $300 million all-stock deal - TipRanks
Gyre, Cullgen Merge In $300M All-Stock Deal - Law360
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 8.2%Should You Buy? - MarketBeat
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead - Stocktwits
H.C. Wainwright reiterates Buy on Gyre Therapeutics stock By Investing.com - Investing.com UK
H.C. Wainwright reiterates Buy on Gyre Therapeutics stock - Investing.com Nigeria
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger - TipRanks
GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Gyre Therapeutics (NASDAQ: GYRE) inks $300M all-stock Cullgen deal - Stock Titan
Gyre Therapeutics, Inc. Announces to Appoint Ying Luo as CEO, Effective March 2, 2026 - marketscreener.com
Gyre Therapeutics enters into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline - marketscreener.com
Gyre Therapeutics Enters Into Agreement To Acquire Cullgen To Gain Targeted Protein Degradation Platform And Pipeline - TradingView
Gyre Therapeutics to acquire Cullgen for $300 million - Investing.com
Gyre Therapeutics Enters into Agreement to Acquire Cullgen - GlobeNewswire
getLinesFromResByArray error: size == 0 - mfd.ru
Gyre Therapeutics, Inc. entered into an agreement to acquire Cullgen Inc. - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 111% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Risks Report: Can Gyre Therapeutics Inc expand into new marketsJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
Big Picture: How do insiders feel about Gyre Therapeutics Inc2025 Valuation Update & Trade Opportunity Analysis - baoquankhu1.vn
GYREGyre Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Aug Selloffs: Can Gyre Therapeutics Inc expand into new marketsJuly 2025 Earnings & Accurate Intraday Trading Signals - baoquankhu1.vn
Gyre Therapeutics Inc Azioni (GYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):